Jpmorgan Chase & CO Assembly Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.65 - $1.25 $39 - $76	-61 Reduced 39.35%	94 $0
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.13 $52 - $67	60 Added 63.16%	155 $0
Q1 2023 May 11, 2023	BUY	$0.8 - $1.74 $0 - $1	1 Added 1.06%	95 $0
Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.34 $10,580 - $14,564	-6,224 Reduced 98.51%	94 $0
Q2 2022 Aug 11, 2022	SELL	$1.35 - $2.29 $11,435 - $19,398	-8,471 Reduced 57.28%	6,318 $13,000

Q1 2022 May 11, 2022	BUY	$1.46 - $2.45 $21,454 - $36,002	14,695 Added 15632.98%	14,789 $30,000
Q4 2021 Feb 10, 2022	SELL	$2.13 - $3.46 $6,115 - $9,933	-2,871 Reduced 96.83%	94 $0
Q3 2021 Nov 12, 2021	BUY	$3.14 - $3.9 $9,310 - $11,563	2,965 New	2,965 $10,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.